Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2022-10-13 Board/Management Inform…
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of a new Director, Deneen Vojta, M.D., to the Board of Hikma Pharmaceuticals Plc. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The presence of 'RNS Number' and the closing statement about RNS distribution confirms it is a regulatory announcement, but the core subject matter dictates the specific filing type.
2022-10-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and explicitly mentions 'NOTIFICATION OF MAJOR HOLDINGS' and 'RNS Number'. The content details changes in voting rights percentages (e.g., 5.090000% and 0.590000%) held by BlackRock, Inc. This structure and content are characteristic of regulatory filings related to significant changes in share ownership thresholds. The presence of 'RNS Number' suggests it was released via the Regulatory News Service, but the core content is a specific notification about shareholdings. This aligns perfectly with the definition for Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'.
2022-10-05 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and contains structured data fields typical of regulatory filings concerning changes in significant share ownership. Specifically, it details an 'acquisition or disposal of voting rights' by 'BlackRock, Inc.' in 'Hikma Pharmaceuticals Plc' and reports the resulting percentage of voting rights (5.680000%). This format and content directly correspond to the notification requirements for major shareholdings crossing specific thresholds, which aligns with the definition for Major Shareholding Notification (MRQ). The presence of 'RNS Number' and the date structure further confirms it is a formal regulatory disclosure.
2022-10-04 English
Block listing Interim Review
Remuneration Information Classification · 99% confidence The document is explicitly titled 'RNS Number : 6090B' and contains the header 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Block Listing Six Monthly Return' for various stock option and incentive plans, covering the period from April 1, 2022, to September 30, 2022. This type of mandatory disclosure regarding the status of unallotted securities under employee share schemes, issued via the RNS system, fits best under the general 'Regulatory Filings' category (RNS), as there is no specific code for 'Block Listing Return'. It is not an Earnings Release (ER), Annual Report (10-K), or a Director's Dealing (DIRS).
2022-10-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification filed via RNS (Regulatory News Service) by Hikma Pharmaceuticals Plc. The content explicitly states the 'Total Voting Rights and Capital' as of a specific date (30 September 2022) and references the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules. This type of announcement, which reports on the total number of shares with voting rights, is a mandatory regulatory disclosure. While it relates to capital structure, it is not a financing event (CAP) or a share repurchase (POS). It is a specific regulatory update concerning share capital used for shareholder notification purposes. Since it is a mandatory, periodic regulatory disclosure that doesn't fit the specific categories like 10-K, ER, or DIV, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for mandatory regulatory updates not covered elsewhere. The document length is short (3636 chars), but it is the primary filing itself, not an announcement *about* a filing.
2022-10-03 English
Director changes and update on AGM 2022 resolution
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of two new Directors (Laura Balan and Victoria Hull) to the Board of Hikma Pharmaceuticals Plc. It also provides an update regarding shareholder votes from the previous Annual General Meeting (AGM) concerning director re-election. The core subject matter is changes in senior management/board composition. This directly aligns with the definition for Board/Management Information (MANG). Although it mentions the AGM and director re-election votes, the primary focus is the *result* of governance changes (new appointments) rather than the voting results themselves (DVA) or the AGM presentation materials (AGM-R).
2022-09-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.